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Abstract
Background: The goal of this study is to evaluate the effectiveness of S-1/Oxaliplatin vs. Doxifluridine/Oxaliplatin regimen
and to identify miRNAs as potential prognostic biomarkers in gastric cancer patients. The expression of candidate miRNAs
was quantified from fifty-five late stage gastric cancer FFPE specimens.
Experimental Design: Gastric cancer patients with KPS.70 were recruited for the trial. The control group was treated with
400 mg/twice/day Doxifluridine plus i.v. with Oxaliplatin at 130 mg/m
2/first day/4 week cycle. The testing group was
treated with S-1 at 40 mg/twice/day/4 week cycle plus i.v. with Oxaliplatin at 130 mg/m
2/first day/4 week cycle. Total RNAs
were extracted from normal and gastric tumor specimens. The levels of miRNAs were quantified using real time qRT-PCR
expression analysis.
Results: The overall objective response rate (CR+PR) of patients treated with S-1/Oxaliplatin was 33.3% (CR+PR) vs. 17.6%
(CR+PR) with Doxifluridine/Oxaliplatin for advanced stage gastric cancer patients. The average overall survival for patients
treated with S-1/Oxaliplatin was 7.80 month vs. 7.30 month with patients treated with Doxifluridine/Oxaliplatin. The
expression of miR-181b (P=0.022) and miR-21 (P=0.0029) was significantly overexpressed in gastric tumors compared to
normal gastric tissues. Kaplan-Meier survival analysis revealed that low levels of miR-21 expression (Log rank test, hazard
ratio: 0.17, CI=0.06–0.45; P=0.0004) and miR-181b (Log rank test, hazard ratio: 0.37, CI=0.16–0.87; P=0.018) are closely
associated with better patient’s overall survival for both S-1 and Doxifluridine based regimens.
Conclusion: Patients treated with S-1/Oxaliplatin had a better response than those treated with Doxifluridine/Oxaliplatin.
miR-21 and miR-181b hold great potential as prognostic biomarkers in late stage gastric cancer.
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Introduction
Gastric cancer remains one of the most common forms of
cancer worldwide with approximately 870,000 new cases and
650,000 deaths per year. Gastric cancer is one of the most
common causes of cancer death in China [1]. The early clinical
detection of gastric cancer was less than 15%, and about 85%
cases were advanced gastric cancer [2]. The average mortality rate
of gastric cancer in China is over 26% for the male and 15% for
the female. Gastric cancer is a rather complex and enigmatic
disorder and many factors likely lead to the development of the
disease. Epigenetics plays key role in gastric cancer development
and mounting evidence showed that non-coding miRNAs are one
of the major contributors to gastric cancer.
miRNAs are a class of small noncoding RNA of 20–22
nucleotides in length, which are processed from larger pre-
miRNAs by the RNase III enzyme Dicer (DICER1) into miRNA
duplexes [3]. One strand of this duplex associates with the RNA-
induced silencing complex (RISC), whereas the other strand is
generally degraded by cellular nucleases [3]. The miRNA–RISC
complex binds to specific mRNA targets, leading to translational
repression or cleavage of these mRNAs. Thus, miRNAs modulate
protein expression by promoting RNA degradation, inhibiting
mRNA translation, and in some cases, affecting transcription.
Although miRNA-mediated mRNA degradation occurs in mam-
mals, most mammalian miRNAs are thought to repress target
gene expression at the translational level [4,5,6] via imperfect
base-pairing to the 39-untranslated regions (39-UTRs) of their
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cell with a more precise, immediate and energy-efficient way of
controlling the expression of a given protein [7] as it induces rapid
changes in protein synthesis without excess transcriptional
activation and subsequent steps in mRNA processing. Addition-
ally, translational control of gene expression has the advantage of
being readily reversible, providing the cell with great flexibility in
responding to various stresses.
Fluoropyrimidine based chemotherapy (e.g. S-1/Oxaliplatin
and Doxifluridine/Oxaliplatin) remains as a major treatment
option for advanced gastric cancer patients. Previous studies have
discovered a number of miRNAs associated with chemoresistance
to 5-FU and S1 based therapy in colorectal cancer
[8,9,10,11,12,13]. S-1 is a novel oral dihydropyrimidine dehydro-
genase (DPD) inhibitory fluoropyrimidine (DIF) based on a
biochemical modulation of 5-fluorouracil (5-FU); S-1 contains
tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-
dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a
molar ratio of 1:0.4:1. Doxifluridine is a fluoropyrimidine
derivative and is activated to 5-fluorouracil by uridine phosphor-
ylase, which is more highly expressed in malignant cells. A number
of reports have demonstrated the importance of miRNAs in gastric
cancer [14,15,16,17]. However, currently there is no study on
miRNAs related to flupyrimidine based chemotherapy treatment.
There is an urgent need to discover prognostic biomarkers to assist
the clinical management of advanced gastric cancer as this will
help to select patients who will have survival benefit from the
treatment, avoid the toxicity to non-responders, and reduce the
healthcare cost for patients.
Although several miRNA profiling studies have been reported
to reveal the importance of miRNA in gastric cancer with impact
on cell cycle control, apoptosis, tumor invasion and metastasis
[14,17], currently there is no report to link miRNA with
chemotherapeutic treatments with S-1/Oxaliplatin and Doxiflur-
idine/Oxaliplatin. In this study, we systematically investigate the
relationship of selected candidate miRNAs (e.g. miR-21, miR-
181b, miR-192, miR-140, let-7g) in terms of their clinical utility in
gastric cancer using archival gastric cancer FFPE specimens.
These miRNAs have been previous reported to be associated with
fluoropyrimidine based chemoresistance in colorectal cancer
[9,10,11,12,13]. Pre-chemotherapy samples were chosen from
the S-1/Oxaliplatin and Doxifluridine/Oxaliplatin in advanced
gastric cancer. We have previous demonstrated that miRNAs are
rather stable in FFPE samples and it is ideal for biomarker
discovery [18]. Patients treated with S-1/Oxaliplatin had a better
response than Doxifluridine/Oxaliplatin. However, there is no
difference in overall patient’s survival. We discovered that miR-21
and miR-181b are significantly associated with gastric cancer
outcome with S-1/Oxaliplatin based chemotherapy. To our best
knowledge, this is the first report to demonstrate the prognostic
significance of miRNAs in gastric cancer related to S-1/
Oxaliplatin and Doxifluridine/Oxaliplatin treatment. miR-21
and miR-181b hold great potential as prognostic biomarkers in
late stage gastric cancer.
Methods
Patients and Samples
Clinical sample cohorts used for this study were approved by the
Institution Review Board of Third Affiliated Hospital of Soochow
University. Paraffin blocks containing formalin-fixed specimens of
the tissues (FFPE) were acquired from the archival collections of the
DepartmentofPathology,and used forsubsequentRNAextraction.
The characteristics of these patients are shown in Table 1.
RNA Isolation
Using archival FFPE tissues, separate areas of solid tumor and
normal gastric epithelium were identified using the corresponding
Hematoxylin and Eosin stained sections and cores measuring
1.5 mm in diameter and 2 mm in length (approximately 0.005 g)
were extracted. Subsequently, the samples were treated with
deparaffinization, hydration, proteinase K, and ultimately total
RNAs were isolated by using the TRIZOL reagent ( Invitrogen,
CA, USA ) [18].
Real time qRT-PCR analysis of miRNA expression
The miR-21, miR-140, let-7g, miR-181b, miR-200c, miR-192
specific primers and the internal control RNU44 gene were
purchased from Applied Biosystems (CA, USA). cDNA synthesis
was performed by the High Capacity cDNA Synthesis Kit
(Applied Biosystems) with miRNA specific primers. Real time
quantitative RT-PCR (qRT-PCR) was carried out on an Applied
Biosystems 7500 Real time system (ABI 7500HT instrument) with
miRNA specific primers by TaqMan Gene Expression Assay.
Expression of miRNAs values was normalized according to the
internal RNU44 control, and the relative expression values were
plotted.
Statistical Analysis
All statistical analysis was performed using GraphPad Prism
software 5.0. Gene expression DCt values of miRNAs from each
sample were calculated by normalizing according to internal
control RNU44 expression, and relative quantification values were
plotted. The differences between tumor and normal tissues were
analyzed by Wilcoxon matched-pairs test. A Kaplan-Meier
survival curve was generated by performing a Cox proportional
hazards regression analysis to evaluate the expression level of miR-
21 and miR-181b with survival rate. Statistical significance was set
up to P,0.05 in each test.
Results and Discussion
Tremendous amount of efforts have been focused on discover-
ing predictive and prognostic biomarkers for gastric cancer [19].
Due to the disease complicity of gastric cancer, it still remains a
major challenge to identify clinical useful biomarkers. With the
recognition of the broad impact of miRNAs on multi targets and
pathways, it is of our interest to identify a new class of predictive
and prognostic biomarkers in gastric cancer based on miRNAs.
There are several advantages of using miRNAs as biomarker
compared to mRNA as miRNAs have broad regulatory function,
relatively small numbers and better stability in archival FFPE
samples [18]. We report here that expression levels of miR-181b
and miR-21 constitute strong prognostic factors in advanced
gastric cancer patients on both S-1/Oxaliplatin and Doxiflur-
idine/Oxaliplatin regimens. The Clinical and pathologic param-
eters of gastric cancer patients treated with Doxifluridine/
Oxaliplatin or S-1/Oxaliplatin were listed in Table 1.
Differential expression of miRNAs in gastric cancer
We carefully selected a number of miRNA candidates that have
been previous reported to be associated with fluoropyrimidine
based chemoresistance in colorectal cancer [9,10,11,12,13]. The
expression levels of miRNAs were quantified via real time qRT-
PCR analysis using total RNA extracted from gastric cancer FFPE
specimens and normal gastric tissues as controls. The miRNA
expression levels were further normalized using internal control
RNU44. Most of the miRNAs (e.g. miR-140, miR-200c) we have
quantified shown differential expression between normal and
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miR-200c, was significantly reduced in gastric cancer. miR-200c
has been reported to directly associated with cheomosensitivity
and epithelial-to-mesenchymal transition (EMT) [20]. The
expression of miR-181b (P=0.022) and miR-21 (P=0.0029) was
most significantly overexpressed in gastric tumors compared to
normal gastric tissues (Figure 2). Our results are consistent with
previous reports that these miRNAs were deregulated in gastric
cancer [21].
Association of miR-21 and miR-181b with response to
S-1/Oxaliplatin and Doxifluridine/Oxaliplatin treatment
regimen
The overall objective response rate (CR+PR) of patients treated
with S-1/Oxaliplatin was 33.3% (CR+PR) vs. 17.6% (CR+PR)
with Doxifluridine/Oxaliplatin for stage III and IV gastric cancer
patients. We have selected several miRNAs that have been shown
to be associated with fluoropyrimidine based chemoresistance in
colon cancer [9,10,11,12,13] and systematically evaluated their
potential link with Doxifluridine/Oxaliplatin and S-1/Oxaliplatin
in gastric cancer. The low expression of miR-21 (P=0.001) and
miR-181b (P=0.001) were significantly associated with the S-1/
Oxaliplatin responders (Table 2). This is highly consistent with
previous report that miR-181b expression was associated with S1
treatment in colorectal cancer [8]. It has been reported that miR-
Table 1. Clinical and pathologic parameters of gastric cancer
patients treated with Doxifluridine/Oxaliplatin or S-1/
Oxaliplatin.
Clinical/Pathologic
Parameters
Doxifluridine/
Oxaliplatin
S-1/
Oxaliplatin z/t-test
P
value
Sex
Male 16 23 1.139 0.254
Female 11 5 1.618 0.106
Age Average: 63.3 Average: 62 1.027 0.31
Diagnosis
No metastasis 4 7 0.940 0.347
Metastasis 23 21 0.301 0.763
Tumor size (cm
2) 48.9 60.8 0.678 0.500
Histology
Low differentiation 9 4 1.502 0.133
High differentiation 18 24 0.935 0.349
Tumor stage
Stage III 3 3 0 1.000
Stage IV 24 25 0.143 0.886
Treatment history
No 22 19 0.469 0.638
Yes 5 9 1.115 0.265
KPS score 82.067.1 80.766.8 0.66 0.514
doi:10.1371/journal.pone.0023271.t001
Figure 1. Expression levels of miR-140, miR-192, miR-200c,
let-7g in both normal and gastric cancer specimens.
doi:10.1371/journal.pone.0023271.g001
Figure 2. Expression levels of miR-21 and miR-181b in both
normal and gastric cancer specimens.
doi:10.1371/journal.pone.0023271.g002
Table 2. Association of miR-21 and miR-182b with response
to S-1/Oxaliplatin treatment based on two-way ANOVA
analysis.
miRNA S-1/Oxaliplatin (Treatment cycle) P Value
miR-21 Cycle 3 0.001
miR-181b Cycle 3 0.017
doi:10.1371/journal.pone.0023271.t002
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targeting BCL2 [22]. With regards to miR-21, our results were
consistent with a recent report that suppression of miR-21 by anti-
miR sensitizes pancreatic cancer cell lines to Gemcitabine (a
fluoropyrimidine analog) treatment [23]. However, the favorable
response did not impact patient’s overall survival as the average
overall survival for patients treated with S-1/Oxaliplatin (7.80
month) was similar with patients treated with Doxifluridine/
Oxaliplatin (7.30 month). This is not surprising as often time
favorable response does not translate to survival benefit.
miR-21 and miR-181b were significantly associated with
patient’s survival
To determine whether some of these miRNAs have potential as
prognostic biomarker in gastric cancer, we performed patient’s
survival analysis using Kaplan-Meier survival curve by Multi
variant Cox regression analysis. Kaplan-Meier survival analysis by
Cox regression revealed that low levels of miR-21 expression (Log
rank test, hazard ratio: 0.17, CI=0.06–0.45; P=0.0004) and miR-
181b (Log rank test, hazard ratio: 0.37, CI=0.16–0.87; P=0.018)
are closely associated with better patient’s overall survival for both
S-1 and Doxifluridine based regimens (Figure 3). The importance
of miR-21 and miR-181b in gastric cancer was strongly supported
by a recent report that the expressions of miR-21 and miR-181b
were activated by STAT3 mediated by IL-6. miR-21 and miR-
181b act as an epigenetic switch to inhibit PTEN and CYLD
tumor suppressors, leading to increased NF-kB activity required to
maintain the transformed state [24]. We also revealed that the
expression of both miR-21 and miR-181b is positively associated
in terms of expression value based on the statistical analysis
(Pearson correlation r=0.38, P=0.018; Spearman correlation
rs=0.38, P=0.018). It is quite conceivable that miR-21 and miR-
181b act as an epigenetic switch in gastric cancer development and
contribute to chemoresistance by modulating key target tumor
suppresser genes such as PDCD4, ANP32A and SMARCA4 genes
[25]. Elevated miR-21 expression has been reported in many
tumor types, suggesting the importance of miR-21 as a bona-fide
oncogene. It has been reported the miR-21 was associated with H.
pylori infection and gastric cancer development, suggesting that
miR-21 could be the potential epigenetic link of inflammation of
H. pylori infection and tumor initiation of gastric cancer [26].
In conclusion, we report here for the first time that the
expression of miR-181b and miR-21 were associated with S-1/
Oxaliplatin and Doxifluridine/Oxaliplatin treatment and patient
survival. It further supports the notion for the potential importance
of miR-181b and miR-21 in gastric cancer disease development. It
establishes a foundation to further explore the underlining
molecular mechanism of gastric cancer development involved
with miR-181b and miR-21, and to fully validate our findings to
the large cohort, multi-center clinical trial patients. miR-181b and
miR-21 may also have potential to be as novel therapeutic targets
in gastric cancer.
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